EyePoint Pharmaceuticals

Press Releases

Jun 06, 2008
Jun 06, 2008
Jun 06, 2008
Jun 04, 2008
pSivida to present at the Rodman & Renshaw Healthcare Conference in Monte Carlo
May 19, 2008
pSivida to present at the Rodman & Renshaw Healthcare Conference in Monte Carlo Boston, MA and Perth, Australia – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that the Company’s Managing Director, Dr Paul Ashton is making a company presentation today at the Rodman & Renshaw 5th
pSivida new trial to treat AMD (age related macular degeneration)
May 09, 2008
pSivida new trial to treat AMD (age related macular degeneration) Boston, MA. and Perth, Australia – pSivida Limited (ASX: PSD, NASDAQ: PSDV, FSE: PSI) announced today that enrolment has begun for a clinical trial to assess the safety and efficacy of Medidur™ FA in conjunction with Lucentis®
Shareholder Meeting - 6 June 2008
May 06, 2008
Shareholder Meeting - 6 June 2008 Boston, MA. and Perth, Australia – pSivida Limited (ASX: PSD, NASDAQ: PSDV, FSE: PSI) announced today that the Federal Court of Australia had ordered the convening of a meeting of shareholders to be held on 6 June 2008 to vote on the proposed Scheme of Arrangement
March Quarter, 2008 Commentary & Highlights
Apr 30, 2008
Commentary and Highlights

- Reincorporation Plan Announced
- Medidur Collaboration Agreement Amended
- BrachySil Pancreatic Cancer Phase IIa Results
- Pfizer R&D Quarterly Payments Commence
pSivida proposed reincorporation in the US
Apr 18, 2008
pSivida proposed reincorporation in the US Boston, MA and Perth, Australia (April 18, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, FSE:PSI) today announced that it proposes to reincorporate in the United States. The reincorporation, which is subject to Australian Federal Court and shareholder
pSivida clears Opes Prime overhang
Apr 15, 2008
pSivida appoints new Company Secretary Boston, MA and Perth, Australia (April 15, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) is pleased to announce that all the Company’s shares subject to Opes Prime margin lending facilities (approximately 14m ordinary shares) have been sold in an
pSivida appoints new Company Secretary
Mar 27, 2008
pSivida appoints new Company Secretary Boston, MA and Perth, Australia (March 27, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that it has appointed Mr Winton Willesee as the Australian Company Secretary. Mr Willesee has broad experience in the company administration of
Open Briefing®. pSivida. Alimera Agreement Amendment
Mar 19, 2008
Open Briefing®. pSivida. Alimera Agreement Amendment pSivida Limited Level 12, BGC Building 28 The Esplanade Perth, Western Australia 6000 Date of lodgement: 19-Mar-2008 Title: Open Briefing®. pSivida. Alimera Agreement Amendment Record of interview: corporatefile.com.au pSivida Ltd.
pSivida generates up to A$82m from licensing amendment with Alimera
Mar 17, 2008
pSivida generates up to A$82m from licensing amendment with Alimera ATLANTA / BOSTON, March 17, 2008 - Alimera Sciences and pSivida Ltd (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that they have amended their license and collaboration agreement relating to Medidur™ FA, the companies’ Phase
pSivida to present at Sachs Conference - Boston
Feb 25, 2008
pSivida to present at Sachs Conference - Boston Boston, MA and Perth, Australia (February 25, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that the Company’s Managing Director, Dr Paul Ashton is making a company presentation in Boston today at the Sachs Associates 7th
pSivida receives first R&D payments from Pfizer
Feb 20, 2008
pSivida receives first R&D payments from Pfizer Boston, MA and Perth, Australia (February 20, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced the receipt of US$500k as the first quarterly research and development payment from Pfizer under the terms of the exclusive
pSivida Quarterly Cash Flow – 31 December 2007 Commentary and Highlights
Jan 31, 2008
Commentary and Highlights

- First R&D funding payments from Pfizer to commence
- BrachySil Pancreatic Cancer Study Results
- pSiNutria Business sold to Intrinsiq
pSivida pancreatic cancer results released
Jan 29, 2008
pSivida pancreatic cancer results released Boston, MA and Perth, Australia (January 29, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced the results of the Phase IIa clinical trial of BrachySilTM for the treatment of advanced, inoperable pancreatic cancer presented at the
BrachySil in Pancreatic Cancer Study Results to be presented at the ASCO Gastrointestinal Cancers Symposium
Jan 23, 2008
BrachySil in Pancreatic Cancer Study Results to be presented at the ASCO Gastrointestinal Cancers Symposium Boston, MA and Perth, Australia (January 23, 2008) – pSivida Limited (NASDAQ: PSDV, ASX: PSD, FF: PSI), a global drug delivery company, today announced that the final results of the recently
pSivida sells pSiNutria to Intrinsiq(UK)
Jan 21, 2008
pSivida sells pSiNutria to Intrinsiq(UK) Boston, MA and Perth, Australia (January 21, 2008) – pSivida Limited (NASDAQ: PSDV, ASX: PSD, FF: PSI), a global drug delivery company, and Intrinsiq Materials Cayman Limited today announced that the assets of pSiNutria Limited, a wholly owned subsidiary of
Displaying 301 - 319 of 319
EyePoint Pharmaceuticals